ArticleAmerican journal of translational research2025
Gut microbiota dysbiosis in alcoholic fatty liver disease: distinct microbial communities and biochemical alterations.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut microbiome in alcohol-associated liver disease: interactions and therapeutic strategies.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the gut microbiota composition among patients with alcoholic fatty liver disease (AFLD), individuals with alcohol use disorder (AUD) without liver damage, and healthy controls, and to investigate correlations between microbial profiles and liver health.
methodsA retrospective analysis was conducted on 34 participants: 14 with AFLD, 10 with AUD without liver damage, and 10 healthy controls. Blood biochemical markers, liver function tests, lipid profiles, and gut microbiota composition were assessed. Gut microbiota was analyzed via high-throughput 16S rRNA gene sequencing. Alpha and beta diversity indices were calculated, and group-specific microbial taxa were identified.
resultsAFLD patients showed a decreased Firmicutes/Bacteroidetes ratio and an increased abundance of Bacteroidetes, indicating gut dysbiosis compared to the other groups. Biochemical markers, including triglycerides, alanine aminotransferase, gamma-glutamyl transferase, and cholinesterase, were significantly altered in AFLD patients (all P > 0.05). Beta diversity analysis revealed distinct microbial communities in the AFLD group. Notably, taxa such as Megamonas and Selenomonadales were enriched in AFLD, while beneficial genera like Ruminococcus and Faecalibacterium were significantly reduced.
conclusionAFLD is associated with marked gut microbiota alterations and distinct microbial signatures, which correlate with liver dysfunction and biochemical abnormalities, highlighting the role of dysbiosis in disease pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.